Clinical Trial Update: Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SB683699 in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• SB683699 (SB683699)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED